Beyond Eylea: Why Regeneron's Deep Pipeline and Antibody Tech Could Signal a Buying Opportunity
As Regeneron Pharmaceuticals shares trade significantly off recent highs, a closer look reveals a company built for sustained innovation. With its foundational VelociSuite platform, a diversified portfolio led by Dupixent, and a fortress balance sheet, analysts argue the current valuation may not fully capture its long-term potential.